Vaccine therapies for patients with glioblastoma

Eli T. Sayegh, Taemin Oh, Shayan Fakurnejad, Orin Bloch, Andrew T. Parsa

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Glioblastoma (GBM) is a high-grade glial tumor with an extremely aggressive clinical course and a median overall survival of only 14.6 months following maximum surgical resection and adjuvant chemoradiotherapy. A central feature of this disease is local and systemic immunosuppression, and defects in patient immune systems are closely associated with tumor progression. Immunotherapy has emerged as an important adjuvant in the therapeutic armamentarium of clinicians caring for patients with GBM. The fundamental aim of immunotherapy is to augment the host antitumor immune response. Active immunotherapy utilizes vaccines to stimulate adaptive immunity against tumor-associated antigens. A vast array of vaccine strategies have advanced from preclinical study to active clinical trials in patients with recurrent or newly diagnosed GBM, including those that employ peptides, heat shock proteins, autologous tumor cells, and dendritic cells. In this review, the rationale for glioma immunotherapy is outlined, and the prevailing forms of vaccine therapy are described.

Original languageEnglish (US)
Pages (from-to)531-546
Number of pages16
JournalJournal of Neuro-Oncology
Volume119
Issue number3
DOIs
StatePublished - Sep 20 2014
Externally publishedYes

Fingerprint

Active Immunotherapy
Glioblastoma
Immunotherapy
Vaccines
Adjuvant Chemoradiotherapy
Neoplasms
Adaptive Immunity
Neoplasm Antigens
Heat-Shock Proteins
Glioma
Neuroglia
Immunosuppression
Dendritic Cells
Immune System
Clinical Trials
Peptides
Survival
Therapeutics

Keywords

  • Glioblastoma
  • Glioma
  • Immunotherapy
  • Vaccine

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Vaccine therapies for patients with glioblastoma. / Sayegh, Eli T.; Oh, Taemin; Fakurnejad, Shayan; Bloch, Orin; Parsa, Andrew T.

In: Journal of Neuro-Oncology, Vol. 119, No. 3, 20.09.2014, p. 531-546.

Research output: Contribution to journalReview article

Sayegh, ET, Oh, T, Fakurnejad, S, Bloch, O & Parsa, AT 2014, 'Vaccine therapies for patients with glioblastoma', Journal of Neuro-Oncology, vol. 119, no. 3, pp. 531-546. https://doi.org/10.1007/s11060-014-1502-6
Sayegh, Eli T. ; Oh, Taemin ; Fakurnejad, Shayan ; Bloch, Orin ; Parsa, Andrew T. / Vaccine therapies for patients with glioblastoma. In: Journal of Neuro-Oncology. 2014 ; Vol. 119, No. 3. pp. 531-546.
@article{eb356dea193e468681222167526d99d1,
title = "Vaccine therapies for patients with glioblastoma",
abstract = "Glioblastoma (GBM) is a high-grade glial tumor with an extremely aggressive clinical course and a median overall survival of only 14.6 months following maximum surgical resection and adjuvant chemoradiotherapy. A central feature of this disease is local and systemic immunosuppression, and defects in patient immune systems are closely associated with tumor progression. Immunotherapy has emerged as an important adjuvant in the therapeutic armamentarium of clinicians caring for patients with GBM. The fundamental aim of immunotherapy is to augment the host antitumor immune response. Active immunotherapy utilizes vaccines to stimulate adaptive immunity against tumor-associated antigens. A vast array of vaccine strategies have advanced from preclinical study to active clinical trials in patients with recurrent or newly diagnosed GBM, including those that employ peptides, heat shock proteins, autologous tumor cells, and dendritic cells. In this review, the rationale for glioma immunotherapy is outlined, and the prevailing forms of vaccine therapy are described.",
keywords = "Glioblastoma, Glioma, Immunotherapy, Vaccine",
author = "Sayegh, {Eli T.} and Taemin Oh and Shayan Fakurnejad and Orin Bloch and Parsa, {Andrew T.}",
year = "2014",
month = "9",
day = "20",
doi = "10.1007/s11060-014-1502-6",
language = "English (US)",
volume = "119",
pages = "531--546",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Vaccine therapies for patients with glioblastoma

AU - Sayegh, Eli T.

AU - Oh, Taemin

AU - Fakurnejad, Shayan

AU - Bloch, Orin

AU - Parsa, Andrew T.

PY - 2014/9/20

Y1 - 2014/9/20

N2 - Glioblastoma (GBM) is a high-grade glial tumor with an extremely aggressive clinical course and a median overall survival of only 14.6 months following maximum surgical resection and adjuvant chemoradiotherapy. A central feature of this disease is local and systemic immunosuppression, and defects in patient immune systems are closely associated with tumor progression. Immunotherapy has emerged as an important adjuvant in the therapeutic armamentarium of clinicians caring for patients with GBM. The fundamental aim of immunotherapy is to augment the host antitumor immune response. Active immunotherapy utilizes vaccines to stimulate adaptive immunity against tumor-associated antigens. A vast array of vaccine strategies have advanced from preclinical study to active clinical trials in patients with recurrent or newly diagnosed GBM, including those that employ peptides, heat shock proteins, autologous tumor cells, and dendritic cells. In this review, the rationale for glioma immunotherapy is outlined, and the prevailing forms of vaccine therapy are described.

AB - Glioblastoma (GBM) is a high-grade glial tumor with an extremely aggressive clinical course and a median overall survival of only 14.6 months following maximum surgical resection and adjuvant chemoradiotherapy. A central feature of this disease is local and systemic immunosuppression, and defects in patient immune systems are closely associated with tumor progression. Immunotherapy has emerged as an important adjuvant in the therapeutic armamentarium of clinicians caring for patients with GBM. The fundamental aim of immunotherapy is to augment the host antitumor immune response. Active immunotherapy utilizes vaccines to stimulate adaptive immunity against tumor-associated antigens. A vast array of vaccine strategies have advanced from preclinical study to active clinical trials in patients with recurrent or newly diagnosed GBM, including those that employ peptides, heat shock proteins, autologous tumor cells, and dendritic cells. In this review, the rationale for glioma immunotherapy is outlined, and the prevailing forms of vaccine therapy are described.

KW - Glioblastoma

KW - Glioma

KW - Immunotherapy

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84919400100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919400100&partnerID=8YFLogxK

U2 - 10.1007/s11060-014-1502-6

DO - 10.1007/s11060-014-1502-6

M3 - Review article

C2 - 25163836

AN - SCOPUS:84919400100

VL - 119

SP - 531

EP - 546

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -